Physician profile
Michael Ryder
NPI 1659598589
$5,416.78
in general payments reported to CMS, 2019-2025
45 companies · $1,343 in 2025
The $1,343 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,700 · 2020: $356 · 2021: $228 · 2022: $538 · 2023: $503 · 2024: $749 · 2025: $1,343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,594.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,594.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $510.42 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $466.89 | 2021-2025 | Rexulti, Nuedexta |
| Abbvie INC. | $446.44 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $444.65 | 2019-2025 | Jardiance, Synjardy, Ofev |
| Lilly USA, LLC | $393.14 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Pfizer INC. | $357.02 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $338.82 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Axsome Therapeutics, INC. | $205.84 | 2024-2025 | Auvelity |
| Novartis Pharmaceuticals Corporation | $199.01 | 2019-2022 | |
| Allergan, INC. | $170.29 | 2019-2020 | |
| Glaxosmithkline, LLC. | $159.11 | 2019-2025 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $153.91 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Janssen Pharmaceuticals, INC | $136.74 | 2019-2022 | |
| Amarin Pharma, INC. | $124.12 | 2019-2020 | |
| Abbott Laboratories | $101.38 | 2021-2024 | Freestyle Libre 3 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ryder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.